Molecular therapeutics in pancreas cancer

Table 3 Summary of selected ongoing clinical trials evaluating molecular therapies in pancreatic ductal adenocarcinoma (according to http://www.clinicaltrials.gov, accessed July 2015)

Category	Clinical trial number	PDA setting	Medications studied	Phase	Status	Estimated completion
Tumor suppressor genes
	NCT01585805	Locally advanced/metastatic	Gem and Cisplatin ± Veliparib vs Veliparib alone	II	Recruiting	07/2017
	NCT01296763	Advanced	Irinotecan + Cisplatin + Mitomycin C ± Olaparib	I/II	Ongoing, not recruiting	01/2014
Recombinant hyaluronidase
	NCT01959139	Metastatic	FOLFIRINOX ± PEGPH20	I/II	Recruiting	12/2017
	NCT01839487	Metastatic	Gem + Nab-paclitaxel vs Gem + Nab-paclitaxel + PEGPH20	II	Recruiting	04/2016
Vaccine therapy
	NCT02004262	Metastatic	Cy + GVAX + CRS-207 vs Chemotherapy vs CRS-207	II	Recruiting	12/2016
	NCT01072981	Adjuvant	Chemotherapy vs Chemo-radiotherapy ± Algenpantucel-L	III	Ongoing, not recruiting	06/2016
	NCT01836432	Neoadjuvant	FOLFIRINOX ± Algenpantucel-L	III	Recruiting	09/2015
Immune checkpoint	NCT02472977	Metastatic	Ulocuplumab (CXCR4) and nivolumab (PD1)	IB	Recruiting	7/2017
CAR-T cell therapy
	NCT01897415	Metastatic	Autologous redirected RNA mesothelin specific CAR-T cells	I	Not recruiting	01/2015
	NCT01583686	Metastatic	CAR-T cell receptor	I/II	Recruiting	12/2018
Micro-RNA-21 targeted therapy
	NCT01274455	Locally advanced	Gem + Plasmid DNA CYL-02	I	Not recruiting	12/2013
Signal transduction inhibitors
Janus kinase targeted	NCT02119663	Locally advanced/metastatic	Capecitabine + Ruxolitinib vs Capecitabine + Placebo	III	Recruiting	06/2017
	NCT02117479	Locally advanced/metastatic	Capecitabine + Ruxolitinib vs Capecitabine + Placebo	III	Recruiting	12/2015
Wnt targeted	NCT02050178	Metastatic	OMP-54F28 + Gem-Nab-paclitaxel	I	Recruiting	12/2016
	NCT01764477	Metastatic	PRI-724 + Gem	I	Recruiting	03/2016
Notch inhibitor	NCT01647828	Locally advanced/metastatic	OMP-59R5 + Gem-Nab-paclitaxel	I/II	Recruiting	01/2016
TGF-β inhibitor	NCT01373164	Locally advanced/metastatic	LY2157299 + Gem	I/II	Not recruiting	11/2015

PDA: Pancreas ductal adenocarcinoma; Gem: Gemcitabine; FOLFIRINOX: 5-fluorouracil, leucovorin, irinotecan, oxaliplatin; CAR-T: Chimeric antigen receptor T cell; TGF-β: Transforming growth factor-β; Cy: Cyclophosphamide.